Physicians' Academy for Cardiovascular Education

A marriage of clinical trial results and imaging findings with icosapent ethyl

Results of the EVAPORATE trial

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Video navigation menu

  • Results of the EVAPORATE study 00:54
  • Start of the discussion: mechanism of action, inertness of placebo 04:42
  • Discussion: low attenuation plaque volume as primary end point, heterogeneity of treatment effect, calcified plaques 08:50
  • Discussion: likely multifactorial effects, stenosis 14:26

Educational information

The educational objective of this video is to provide cardiovascular physicians with the latest findings and interpretations of studies.


- Fabrice Martens, MD, PhD is a cardiologist at the Deventer Hospital, The Netherlands

- Ph. Gabriel Steg, MD is a cardiologist in the Hôpital Bichat, Paris, France. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK.

- Matthew J Budoff, MD is investigator at Lundquist Institute and Professor of Medicine, David Geffen School of Medicine at UCLA and Program Director and Director of Cardiac CT, Division of Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA, USA.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


This educational program was sponsored by unrestricted educational grants from Amarin.

Read our summary of the EVAPORATE study Read our summary of the REDUCE-IT trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: